There is a patient support brochure available for patients who have been prescribed XELJANZ for the treatment of:

  • Rheumatoid Arthritis (RA)
  • Psoriatic Arthritis (PsA)
  • Ulcerative Colitis (UC)

These brochures contain information on:

  • How XELJANZ works
  • Dosing and administration
  • Key safety information on considerations before, during and after treatment

Digital versions of these brochures are available to download below. If you wish to receive a printed copy of any of these brochures please contact your local Pfizer representative.

RA Patient Brochure
This brochure should only be given to patients who have been prescribed XELJANZ for RA.

PsA Patient Brochure
This brochure should only be given to patients who have been prescribed XELJANZ for PsA.

UC Patient Brochure
This brochure should only be given to patients who have been prescribed XELJANZ for UC.

XELJANZ patient information leaflets (PIL's) are available to download here from Medicines.ie


PP-XEL-IRL-0648 July 2021

XELJANZ Summary of Product Characteristics.

▼This product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions. Legal Category: S1A